Goodsurance

Drug prices & Part D

Face-to-Face Drug Price Talks Between Medicare and Manufacturers Close Today on 15 High-Cost Drugs

September 11 is the statutory deadline for in-person and virtual negotiation meetings in Medicare's third drug price negotiation cycle. Written offers are next, with a final CMS offer due September 30 and manufacturer responses due by November 1.

By the Goodsurance editorial teamSeptember 11, 2026

Today is the last day CMS can hold in-person or virtual meetings with drug manufacturers in the third cycle of the Medicare Drug Price Negotiation Program. After today, the parties may only communicate through written offers and responses.

The third cycle covers 15 drugs, including the first medications payable under Medicare Part B ever selected for the program. Negotiations occur throughout 2026, and any agreed prices would take effect January 1, 2028.

Today is the last day Medicare and drug companies can meet face-to-face on prices for 15 high-cost drugs. Written offers follow, with a CMS deadline of September 30.

Under the timeline CMS set in its final guidance for the third cycle, CMS sent each manufacturer an initial offer no later than June 1, 2026. If a manufacturer submitted a counteroffer, CMS could invite up to two additional face-to-face or virtual meetings. That window closes today.

CMS must now issue a final written offer on each drug no later than September 30, 2026. Manufacturers then have until November 1 to accept or decline. A manufacturer that declines faces an escalating excise tax on affected drugs or must withdraw those products from Medicare and Medicaid.

All 15 drug companies whose products were selected for the third cycle chose to participate in the program, according to CMS. If agreements are reached, CMS is expected to publish the negotiated maximum fair prices after the November 1 deadline. Those prices would reduce out-of-pocket costs for beneficiaries starting in 2028.

In plain words

Medicare has a program to lower the price of certain expensive drugs. Today is the last day Medicare can meet in person or by video with drug companies to talk about those prices. They are working on prices for 15 drugs. After today, they can only send each other written messages. Medicare must send its final price offer by September 30. Drug companies then have until November 1 to say yes or no. If they say yes, the new lower prices start on January 1, 2028. Lower prices could mean lower costs for people with Medicare who take those drugs.

Source: CMS
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Medicare Part D Drug Spending Is Projected to Nearly Double by 2035, With GLP-1 Prescriptions as the Primary Driver

A KFF analysis of the 2026 Medicare Trustees Report projects annual Part D spending will climb from 181 billion dollars in 2025 to 346 billion dollars in 2035, a pace driven largely by surging use of GLP-1 drugs for diabetes and weight loss. The data arrives six weeks before open enrollment opens.

September 11, 2026

Drug prices & Part D

Comment Period Closes September 18 on How Drug Companies Must Apply Medicare-Negotiated Prices at Clinics and Doctor's Offices Starting in 2028

A CMS draft guidance describes the step-by-step process manufacturers must follow to make sure negotiated Medicare prices actually reach patients receiving infused or injected medicines at a doctor's office or outpatient clinic. Public comments are due September 18, 2026.

September 3, 2026

Drug prices & Part D

Medicare's Third Drug Negotiation Cycle Enters Its Final Month Before CMS Must Send Written Offers on 15 Drugs

CMS must issue final written maximum fair price offers to all 15 drug manufacturers in the third negotiation cycle by September 30. Companies then have until October 31 to accept or reject, with any agreed prices published by November 30 and taking effect in January 2028.

September 2, 2026

Drug prices & Part D

With Open Enrollment Weeks Away, Medicare Rights Center Recaps What the Inflation Reduction Act Has Delivered for Part D in 2026

An August 27 analysis from the Medicare Rights Center outlines the drug law's current protections, including a first-ever Part D out-of-pocket cap and ten negotiated drug prices that took effect in January.

August 30, 2026

Drug prices & Part D

CMS Opens a New Database This Fall to Track Discounted Drugs Sold Through Medicare Part D

Starting October 1, 2026, safety-net health providers that buy drugs at a 340B discount can voluntarily report those Part D claims to CMS, filling a gap that has made it harder to enforce inflation rebate rules accurately.

August 29, 2026

Drug prices & Part D

Medicare Drug Plans Paid 587.7 Million Dollars for Prescriptions That Had Already Gone Over the Counter, OIG Finds

A federal audit found that from 2021 through 2023, Part D plans paid hundreds of millions of dollars for five drugs that had already switched from prescription-only to over-the-counter status, because CMS did not update its reference files quickly enough.

August 28, 2026